LaSalle Venture Advisers
Robert F. Williamson, III has been active in starting and assisting public and private companies through his consultancy, LaSalle Venture Advisers. He is also the CEO of privately held PharmAkea, an oncology and fibrosis drug development company, financed through a partnership with Celgene (NASDAQ: CELG). He is currently on the boards of privately held Aegle, Sidecar & Rickshaw Therapeutics and the Coulter Center. He is also active in assisting public and private companies through his consultancy, LaSalle Venture Advisers. Previously, as an early Director, he helped finance, grow, take public and sell Pharmasset, Inc. (NASDAQ: VRUS), which was bought by Gilead (NASDAQ:GILD) for $11B. He was also on the board of Progen Pharmaceuticals (NASDAQ: PGLA) after he sold CellGate to Progen, and has been on numerous private boards. Earlier, Mr. Williamson was CEO of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which he sold to Protein Design Labs (NASDAQ: PDLI), and COO of DoubleTwist, Inc., acquired in part by Merck (NYSE: MRK) and Hitachi (NYSE: HIT). Before managing life sciences companies, Mr. Williamson was a partner with The Boston Consulting Group. Mr. Williamson started his career as a research assistant for the Federal Reserve Board of Governors in Washington, D.C., supporting monetary policy. He received a B.A. in Economics from Pomona College and an M.B.A. from Stanford GSB.